308 related articles for article (PubMed ID: 21307676)
21. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
23. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
24. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Kuiper JL; Ronden MI; Becker A; Heideman DA; van Hengel P; Ylstra B; Thunnissen E; Smit EF
J Clin Pathol; 2015 Apr; 68(4):320-1. PubMed ID: 25661795
[No Abstract] [Full Text] [Related]
25. Targeted treatment tested as potential cancer cure.
Hayden EC
Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
[No Abstract] [Full Text] [Related]
26. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
27. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Gandara DR; Lara PN; Mack P; Scagliotti G
Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
[No Abstract] [Full Text] [Related]
28. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
[No Abstract] [Full Text] [Related]
29. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
30. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
31. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
[TBL] [Abstract][Full Text] [Related]
32. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
Urata Y; Satouchi M
Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
[No Abstract] [Full Text] [Related]
33. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
Govindan R
J Clin Oncol; 2010 Feb; 28(5):713-5. PubMed ID: 20038722
[No Abstract] [Full Text] [Related]
34. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
35. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
36. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.
Politi K; Ayeni D; Lynch T
Cancer Cell; 2015 Jun; 27(6):751-3. PubMed ID: 26058074
[TBL] [Abstract][Full Text] [Related]
37. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
Gauthier H; Douchet G; Lehmann-Che J; Meignin V; Raynaud C; Sabatier P; de Cremoux H; Poirot B; Culine S; Pouessel D; de Cremoux P
J Thorac Oncol; 2014 Oct; 9(10):e78-9. PubMed ID: 25521408
[No Abstract] [Full Text] [Related]
38. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
39. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
40. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]